The Clinician Limited (The Clinician or the Company), creator of a leading Digital Health data platform focused on Patient Reported Outcome Measures (PROMs), is pleased to announce the successful completion of its Series A Round supported by numerous experienced international investors. The round was led by global technology investor, Allectus Capital and included participation from Wavemaker Partners Singapore, Cure Kids Ventures Investment Fund and New Zealand Investment Venture Fund. The funds will be used to expand marketing, research and development activities and accelerate regional rollout for the Company’s flagship ZEDOC PROMs product, the first of its kind in the Asia Pacific.
ZEDOC is a cloud native SaaS platform which operates within existing clinical workflows and systems to enable the distribution, collection and analysis of PROMs feedback from patients. This real time data monitoring spans multiple patient cohorts, allowing for aggregated assessment and the identification of at risk cases and any intervention required. ZEDOC operates to capture data across the entire care continuum; pre, during and post clinic remotely (e.g. via wearables, health tracker or mobile app). By facilitating data-led treatment eligibility criteria and optimising intervention timing, it is possible for healthcare providers to improve patient outcomes using a patient-centric value-based care approach. By capturing and analysing patient data continuously, health providers are able to reduce admission / readmission levels, raise clinical efficiency and lower total costs.
The completion of the round will allow The Clinician to expand marketing, sales and development in the Asia Pacific, with the Company at the forefront of a growing wave of demand for PROMs globally, initiated by healthcare institutions and public sector regulation. The growth capital will also be used to rollout the ZEDOC platform alongside its existing hospital partners in Singapore, Australia and New Zealand, including supporting the expansion of the Company’s Governmental partner program for nationwide implementation of PROMs systems.
Managing Director and Co-Founder of The Clinician, Tamaryn Hankinson said “we are excited to have so many experienced investors, led by Allectus Capital and Wavemaker Partners, support our mission of helping health providers implement value-based healthcare - optimising patient care while reducing costs. With our founding team comprised of senior physicians, pharma industry specialists and technologists, ZEDOC addresses an urgent need to rebalance high levels of clinical waste in overburdened health systems, reduce rapidly rising expenses and improve outcomes for the growing aging population. Our unique cross-device platform, deep learning capability and API ecosystem can produce actionable insights previously not possible for our healthcare partners.”
The Clinician is a leading Digital Health data platform company focused on capturing, analysing and leveraging Patient Reported Outcome Measures (PROMs) to improve patient treatment and care. Founded and built by senior physicians and healthcare experts for healthcare providers, the Company’s innovative ZEDOC cloud based PROMs platform enables providers to focus on driving better care outcomes while improving organisational effectiveness and reducing costs – delivering value-based care to the patients who need it the most – whether in clinic or remotely. ZEDOC combines real-time patient cohort monitoring, deep learning, mobile/wearable APIs and seamless integration with existing clinical systems. Our data-driven platform is trusted by healthcare providers across Asia Pacific to identify and facilitate optimal treatment, reduce readmissions and improve clinical efficiency. For more information visit www.theclinician.com
Allectus Capital Limited (Allectus) is an investment company with a value focused technology portfolio of unlisted and listed companies. Allectus was formed to invest in, and partner with, potentially disruptive businesses in the technology sector. Allectus is managed by ICM Limited (ICM) and oversees and supports c.US$300m in technology investments, principally in the Asia Pacific and United Kingdom, for clients of ICM. Allectus is an active, long-term investor, supporting both the growth of individual investments and encouraging synergies between our portfolio businesses. Allectus is owned by ICM and UIL Limited (LSE:UTL). For more information visit www.allectuscapital.limited and www.icm.limited.